Emergent BioSolutions (EBS) Operating Expenses (2011 - 2026)

Emergent BioSolutions' Operating Expenses history runs 16 years deep, the most recent figure standing at $145.6 million for Q1 2026.

• On a quarterly basis, Operating Expenses fell 15.5% year-over-year to $145.6 million in Q1 2026; TTM through Mar 2026 was $616.1 million, a 42.1% decrease from a year earlier, with the FY2025 full-year figure at $642.8 million, down 44.22% from the prior year.
• Operating Expenses slipped to $145.6 million in Q1 2026 per EBS's latest filing, from $176.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $630.8 million in Q2 2023 and bottomed at $139.3 million in Q2 2025.
• The 5-year median for Operating Expenses is $285.2 million (2022), against an average of $294.3 million.
• Across the five-year window, Operating Expenses soared 100.44% in 2023 and plunged 69.6% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $385.5 million in 2022, then declined by 16.89% to $320.4 million in 2023, then tumbled by 36.27% to $204.2 million in 2024, then slipped by 13.52% to $176.6 million in 2025, then dropped by 17.55% to $145.6 million in 2026.
• Per Business Quant, the three latest EBS Operating Expenses figures stand at $145.6 million (Q1 2026), $176.6 million (Q4 2025), and $154.6 million (Q3 2025).